Exsight partner alan spiro joins innovative odylia therapeutics

Alan is on the Board of Advisors of Odylia Therapeutics.  Odylia has created a novel paradigm to catalyze the development of gene therapies for rare blinding inherited retinal diseases (IRDs).  Its strategy is to provide a non-profit platform that can achieve significant discounts, efficiencies and economies of scale, so as to lower the costs and accelerate the development of treatments for IRDs from the lab through clinical trials.
Scientists, Advocates Team Up to Launch Odylia Therapeutics to Accelerate Gene Therapy Trials for Rare Conditions Causing Blindness
​New nonprofit organization will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases.
Boston, Mass. — Scientists and advocates today announced the formation of Odylia Therapeutics, a nonprofit corporation dedicated to creating gene therapies for ultra-rare genetic conditions causing blindness. The company’s efforts will concentrate on developing laboratory findings into human clinical trials for select diseases, addressing an unmet need for drug development in an area where there is currently little commercial interest. Odylia Therapeutics is being launched with support from Massachusetts Eye and Ear and the Usher 2020 Foundation, a charitable organization focused on finding cures for rare eye diseases. Read the full release here.